Researchers discover how gene mutation triggers immune disease

Image
ANI Washington D.C. [U.S.A]
Last Updated : Feb 01 2018 | 1:55 PM IST

According to a recent research, a group of scientists have found how a gene mutation affects T cell function to promote immune disorders.

The team then tested a treatment based on the discovery -- successfully fixing donated immune cells from a 16-year-old boy with an abnormally low level of white blood cells called lymphopenia.

The discovery centers on mutation of the gene Gimap5, which is important to the healthy formation and function of CD4+ T cells, one of the immune system's super soldiers against infection and disease.

Scientists noted that the protein associated with the Gimap5 gene (also Gimap5), is important because it regulates a protein that inactivates an enzyme called GSK3.

If GSK3 isn't inactivated it causes DNA damage in T cells that are expanding, causing the cells to not survive or function correctly.

In mice and human blood cells, the researchers tested drugs that inhibit GSK3, improving immune system function in mice and restoring normal T cell function in the human cells.

Study's lead author Kasper Hoebe, PhD, Division of Immunobiology, said, "Our data suggest GSK3 inhibitors will improve T cell survival and function and may prevent or correct immune-related disorders in people with Gimap5 loss-of-function mutations. Therapeutically targeting this pathway may be relevant for treating people with Gimap5 mutations linked to autoimmunity in Type 1 diabetes, systemic lupus erythematosus or asthma."

The scientists associated with the current study said additional research is needed before the data have clinical relevance for patients.

Meanwhile, new experiments are underway to translate the findings into the clinic, Hoebe said.

The scientists are investigating if and how genetic variants in Gimap5 affect GSK3 regulation causing malfunctioning T cells in patients with immune disorders.

They also are exploring the therapeutic potential of GSK3 inhibitors in preclinical mouse models of allergic lung disease and lupus to see if they can improve patient outcomes.

The study was published in journal Nature Communications.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 01 2018 | 1:55 PM IST

Next Story